Skip to main content

AbbVie Inc.

corporate_fare Company Profile

AbbVie Inc.

ABBV·NYSE·Life Sciences·CIK 0001551152

AbbVie is a global, diversified research-based biopharmaceutical company that develops and markets advanced therapies. The company was incorporated in Delaware on April 10, 2012, and became an independent, publicly-traded company on January 1, 2013, following a distribution from Abbott Laboratories. AbbVie operates as a single global business segment, focusing on the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies. This structure allows the Chief Executive Officer to allocate resources and assess performance globally. A global research and development and supply chain organization handles product discovery, development, manufacturing, and supply, while commercial efforts for marketing, sales, and distribution are organized by geographic region or therapeutic area. These activities are supported by a global corporate administrative staff. AbbVie's product portfolio holds leadership positions across immunology, neuroscience, oncology, and aesthetics. Its products include a broad line of therapies for complex and serious diseases, with an extensive immunology portfolio covering rheumatology, dermatology, and gastroenterology.

AbbVie Inc. (NYSE:ABBV) is a publicly traded company in the Life Sciences sector. Wiseek monitors ABBV SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • AbbVie Prices $8 Billion Multi-Tranche Senior Notes Offering
  • AbbVie Secures Rinvoq Exclusivity to 2037, Pledges $100B US Investment, and Reports Robust Pipeline Progress
  • AbbVie Exceeds Revised 2025 EPS Guidance, Reports Strong Q4 & Full-Year Results, and Issues Robust 2026 Outlook
  • AbbVie Lowers Full-Year 2025 EPS Guidance Due to $1.3 Billion Q4 IPR&D Expense

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$61.16B
Net Income
$4.23B
Diluted EPS
$2.36
Op. Cash Flow
$19.03B
Free Cash Flow
$17.82B
Gross Profit
$42.96B
Operating Income
$15.07B
Cash & Equivalents
$5.23B
Total Debt
$2.5B
Debt / Equity
-0.76×
Net Margin
6.9%
Shares Outstanding
1.77B sh
Source: 10-K · filed 2026-02-20 · accession 0001551152-26-000008
$222.88
52-week range · as of 2026-05-08 $176.57 – $244.81
Market cap
$393.78B
Volume
3M (0.5× avg)
3-mo avg 5.9M
Live data · 2026-06-08 19:39 UTC · Market open

show_chartPrice Chart

Loading chart...

feed ABBV - Filings & News (Page 2)

ABBV
Feb 24, 2026, 7:47 PM EST
Filing Type: FWP
Importance Score:
8
Price at Filing: $228.64
Real-time Price: $222.88 info
Change: -$5.76 (-3%) info
Market Cap: $393.783B info
ABBV
Feb 20, 2026, 2:38 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $226.46
Real-time Price: $222.88 info
Change: -$3.58 (-2%) info
Market Cap: $393.783B info
ABBV
Feb 04, 2026, 7:54 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $229.00
Real-time Price: $222.88 info
Change: -$6.12 (-3%) info
Market Cap: $393.783B info
ABBV
Jan 07, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $229.50
Real-time Price: $222.88 info
Change: -$6.62 (-3%) info
Market Cap: $393.783B info